Search results
What's Going With BioNTech Stock On Monday?
Benzinga· 1 day agoMonday, BioNTech SE BNTX reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss...
Analyst Report: BioNTech SE
Morningstar Research via Yahoo Finance· 1 day agoBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious ...
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
Barrons.com· 2 days agoFEATURE U.S.-listed shares of BioNTech were falling Monday after the German company that partnered...
BioNTech Seesaws On Wide Losses, Continuing Covid Slump
Investor's Business Daily· 2 days agoSales of Comirnaty, the BioNTech-Pfizer (PFE)-partnered Covid shot, plummeted 86% to $202 million,...
BioNTech says 90% of 2024 revenues will accrue at end of year
Reuters· 2 days ago, opens new tab was widely used during the pandemic, said on Monday that almost all of its expected...
BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm
Investopedia· 2 days agoAmerican depositary receipts (ADRs) of BioNTech (BNTX) were down less than 1% in intraday trading...
BioNTech says 90% of 2024 revenues will accrue at end of year
WHTC 1450 Holland· 2 days agoFRANKFURT (Reuters) - Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was...
BioNTech says 90% of 2024 revenues will accrue at end of year
Reuters via Yahoo Finance· 2 days agoGermany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would ...
BioNTech Slips To Loss In Q1 On Weak Revenues, Backs FY24 View; Stock Dips In Pre-market
RTT News· 2 days agoGerman Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a loss in its first quarter, compared to prior year's profit with sharply ...
UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year
Reuters via Yahoo Finance· 2 days agoGermany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would ...